Navigation Links
Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
Date:11/5/2011

EAST BRUNSWICK, N.J., Nov. 5, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA® (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.  Additionally, the results from several Savient-sponsored studies highlighting the health-related quality of life and economic impact of inadequately-controlled gout and RCG will also be presented at the meeting.

A post-hoc analysis of data from the pivotal Phase III KRYSTEXXA clinical trials and an open-label extension study further characterized the signs and symptoms of infusion reactions and anaphylaxis and their management in the context of the clinical studies. While all patients studied were pre-medicated to decrease the potential risk of these events, the data also confirmed that risk of infusion reactions and anaphylaxis could be mitigated by the monitoring of serum uric acid (SUA) prior to each infusion and discontinuing of KRYSTEXXA treatment when SUA rises to above 6 mg/dL.

"These data contribute to the growing body of evidence supporting the profile and clinical utility of KRYSTEXXA," said John H. Johnson, Chief Executive Officer and President of Savient Pharmaceuticals. "Savient remains focused on educating healthcare professionals about KRYSTEXXA and its role in helping patients who have not found success with available conventional therapies to gain control of their RCG."

Data from health-related quality-of-life studies provided further insights surrounding the management of gout and RCG, and the relationship between symptom severity and patients' work productivity, healthcare resource utilization and medical costs:
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
2. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
3. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
4. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
5. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
6. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
7. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
8. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
9. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
10. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
11. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 PuraMed BioScience ® , Inc., ... (OTC) medicinal and healthcare products, announced today that ... along with the name,s red and yellow logo. ... name MigraPure ®  going forward. The new ... natural migraine pain reliever will be reintroduced into ...
(Date:7/30/2014)... DUBLIN , July 30, 2014 ... the "Global and Chinese Aseptic Packaging Industry Report ... http://photos.prnewswire.com/prnh/20130307/600769 The Global and ... in-depth study on the current state of the global ... situation. The report provides a basic overview of ...
(Date:7/30/2014)... , July 30, 2014 Stryker brand ambassadors Fred ... at the 3M Championship Champions Tour event near Minneapolis, ... Blaine . Stryker is the official joint replacement ... Starting Friday, August 1 st through Sunday, August 3 ... Zone; an on-site joint health destination located in the Pioneer Press ...
Breaking Medicine Technology:PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3Global and Chinese Aseptic Packaging Industry Report 2014 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5
... May 24, 2011 Reportlinker.com announces that ... in its catalogue: Triple ... http://www.reportlinker.com/p0284621/Triple-Analysis-Leukemia-Lymphoma-and-Peptides.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology This ... strategies in both Leukemia and Lymphoma and ...
... Calif., May 23, 2011 Applied Medical today announced ... business as Covidien) on May 17, 2011 in the ... for infringing a recently issued Applied Medical trocar seal ... products, Civil Action No. CV 11-4203 VBF (AJWx). The ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides 2Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides 3Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides 4Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides 5Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent 2
(Date:7/31/2014)... 2014 “Bivalent, Heteronomy and Natural Killer ... hottest metal bands ~ homeostatic CS science is the ... July Roundup, new on the Bryan William Brickner ... and the cannabinoid system (CS). The line-up links to ... wellness: three directly on homeostasis, two each on the ...
(Date:7/31/2014)... latest blog post, Best Drug Rehabilitation , which offers ... a stay in rehab can make a big difference in ... nine secrets that addicts don’t want others to know. ... addict from a mile away, and totally understand what’s going ... Per Wickstrom . “However, take it from me: spotting addicts ...
(Date:7/31/2014)... 31, 2014 Continuing Education Company ... inaugural Clinical Issues in Primary Care Continuing ... 2014 at the Wailea Beach Marriott Resort and Spa ... has been developed for today's Primary Care practitioners. In ... topics," says Barbara Lyons, VP Education. , The agenda ...
(Date:7/30/2014)... Denver, Colorado (PRWEB) July 30, 2014 ... the skiers wearing orange vests emblazoned with “Blind Skier.” ... Colorado slopes through Foresight Ski Guides , a ... with visually impaired and blind participants (VIPs) for snow ... interested in guiding can learn more and pick up ...
(Date:7/30/2014)... July 31, 2014 Responding to ... environment more responsive to an increasingly diverse patient ... experience and scholarly expertise to the publication of ... care professions: "Diversity and Cultural Competence in Health ... L. Dreachslin, PhD, a professor in the Management ...
Breaking Medicine News(10 mins):Health News:Homeostatic Cannabinoid Science ~ Publius’ July Roundup on the Bryan William Brickner Blog 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 3Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 3Health News:Colorado Non-Profit Foresight Ski Guides Seeking Applications for Blind and Visually Impaired Skiers and Guides for Vail Ski Season 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 3
... Health & Science University researchers have determined exactly how much ... results of this research are being presented from 5 p.m. ... for Therapeutic Radiology and Oncology in Boston. , "Many ... that it doesn,t move in relation to the bony pelvis, ...
... is playing an ever smaller role in the treatment ... and safe radiation therapy techniques. Progress in radiation technology ... This is according to Professor Freek Beekman, who will ... on Wednesday, 24 September. , In his inaugural ...
... bacteria that drive the ailment, study shows , , WEDNESDAY, ... sweet relief to chronic sinusitis sufferers, new Canadian research ... attack the bacteria that cause the discomforting disorder. , ... natural anti-microbial dressing for infected wounds for hundreds of ...
... 24 TransEnterix, an,early-stage, privately-held medical device company ... the Board of Directors has,named Todd M. Pope ... Pope has spent nearly 20 years in the ... neurovascular, and,laparoscopic surgery., Mr. Pope, 43, was ...
... Indianapolis speech, INDIANAPOLIS, Sept. 24 Today Eli ... is set to become the first,pharmaceutical research company to ... At a speech before the Economic Club of Indiana ... outlined the,company,s plans to launch an online registry of ...
... Longstanding Barriers to ... Hearing Better, ... a unique option for people dealing with mild to moderate,hearing loss. ... hearing loss, while concerns about cost,commitments, and inconvenience contribute to only ...
Cached Medicine News:Health News:OHSU Cancer Institute researchers study breathing during radiation 2Health News:Open cancer surgery set to become a thing of the past 2Health News:A Honey of a Sinusitis Treatment 2Health News:A Honey of a Sinusitis Treatment 3Health News:TransEnterix Inc. Names Experienced Medical Device Executive Todd M. Pope as President, CEO 2Health News:Lilly Set to Become First Pharmaceutical Research Company to Disclose Physician Payments 2Health News:Lilly Set to Become First Pharmaceutical Research Company to Disclose Physician Payments 3Health News:Songbird Hearing Provides Revolutionary Alternative for Those Dealing With Hearing Loss 2Health News:Songbird Hearing Provides Revolutionary Alternative for Those Dealing With Hearing Loss 3
The under-patient design of the pediatric full access blanket warms even the tiniest patients while allowing full access for surgeons and staff....
This blanket gently surrounds the child with temperature-controlled air. Use one or both of the enclosed clear plastic drapes to keep warmed air near the skin....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
The multi-access blanket offers access to any part of the patient's body while providing full patient coverage....
Medicine Products: